To investigate whether prostate cancer cell is the target cell for IL–20, we used IHC staining to analyze the expression levels of IL–20’s receptors (IL-20R1, IL-20R2, and IL-22R1) in prostate adenocarcinoma tissue samples from 40 patients. This evidence concerns the gene IL22RA1 and prostate adenocarcinoma.